Evidence map›Paper›PMID 25458856›Full record

ReviewSchizophrenia research2015

GABA abnormalities in schizophrenia: a methodological review of in vivo studies.

Stephan F Taylor, Ivy F Tso

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Schizophrenia research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 4 pooled it
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 4 syntheses or guidelines pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies.Journal of neural transmission (Vienna, Austria : 1996) · 2019
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. The hippocampus as a generative model.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Stephan F TaylorDepartment of Psychiatry, University of Michigan, Ann Arbor, MI, USA. Electronic address: sftaylor@umich.edu.
Ivy F TsoDepartment of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
University of Michigan–Ann Arbor · US

Funding

Magnetic Resonance Spectroscopy in the Psychosis Risk SyndromeR21MH101676 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TAYLOR, STEPHAN F · 2013 to 2014
$428k
NIMH NIH HHS R21 MH101676
6 · The paper itself

Abstract

Abnormalities of GABAergic interneurons are some of the most consistent findings from post-mortem studies of schizophrenia. However, linking these molecular deficits with in vivo observations in patients - a critical goal in order to evaluate interventions that would target GABAergic deficits - presents a challenge. Explanatory models have been developed based on animal work and the emerging experimental literature in schizophrenia patients. This literature includes: neuroimaging ligands to GABA receptors, magnetic resonance spectroscopy (MRS) of GABA concentration, transcranial magnetic stimulation of cortical inhibitory circuits and pharmacologic probes of GABA receptors to dynamically challenge the GABA system, usually in combination with neuroimaging studies. Pharmacologic challenges have elicited behavioral changes, and preliminary studies of therapeutic GABAergic interventions have been conducted. This article critically reviews the evidence for GABAergic dysfunction from each of these areas. These methods remain indirect measures of GABAergic function, and a broad array of dysfunction is linked with the putative GABAergic measures, including positive symptoms, cognition, emotion, motor processing and sensory processing, covering diverse brain areas. Measures of receptor binding have not shown replicable group differences in binding, and MRS assays of GABA concentration have yielded equivocal evidence of large-scale alteration in GABA concentration. Overall, the experimental base remains sparse, and much remains to be learned about the role of GABAergic interneurons in healthy brains. Challenges with pharmacologic and functional probes show promise, and may yet enable a better characterization of GABAergic deficits in schizophrenia.

Indexed as

AnimalsBrainGABA Agentsgamma-Aminobutyric AcidHumansInterneuronsMagnetic Resonance SpectroscopyNeuroimagingSchizophreniaTranscranial Magnetic StimulationGABA Agentsgamma-Aminobutyric AcidBenzodiazepinefMRIMRSPETPsychosisTMS

Identifiers

PMID25458856
PMCPMC4409914
OpenAlexW2159807189

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.